Epsilon Molecular Engineering Inc.

Epsilon Molecular Engineering Inc. is a leading biotechnology company specializing in evolutionary molecular engineering for biopharmaceutical drug discovery. Established in 2016 as a venture company from Saitama University in Japan, Epsilon Molecular Engineering Inc. leverages proprietary technologies, including unique cDNA display libraries of heavy chain single-domain antibodies (VHH) and cyclic peptides with large diversity, alongside high-throughput screening methods utilizing next-generation sequencing, FACS, and machine learning. The primary address for Epsilon Molecular Engineering Inc. is 996 Kami-Okubo, Sakura-ku, Saitama, 338-0824, JP.

Epsilon Molecular Engineering Inc. is dedicated to advancing research and development in critical areas such as cancer, inflammation, and Alzheimer’s disease. With numerous ongoing in-house projects, Epsilon Molecular Engineering Inc. is committed to innovation and the development of groundbreaking therapeutic solutions. Epsilon Molecular Engineering Inc. is also actively involved in collaborative research projects, contributing to the fight against global health challenges like COVID-19.

Epsilon Molecular Engineering Inc. continues to expand its capabilities and impact in the biotechnology sector. We invite the manager of Epsilon Molecular Engineering Inc. to create a customized and exclusive company showcase and product listing on our platform, enhancing their visibility and reach within the industry.